Ana Treviño1, Teresa Cabezas2, Ana Belén Lozano2, Rosa García-Delgado3, Luis Force4, José María Fernández-Montero2, Carmen de Mendoza5, Estrella Caballero6, Vincent Soriano7. 1. Laboratory of Virology, Puerta de Hierro Research Institute and University Hospital, Majadahonda, Madrid, Spain. 2. Hospital de Poniente, Almeria, Spain. 3. Fundación Jimenez Díaz, Madrid, Spain. 4. Hospital de Mataró, Barcelona, Spain. 5. Laboratory of Virology, Puerta de Hierro Research Institute and University Hospital, Majadahonda, Madrid, Spain. Electronic address: cmendoza.cdm@gmail.com. 6. Hospital Vall d'Hebrón, Barcelona, Spain. 7. Infectious Diseases Unit, La Paz University Hospital & IdiPAZ, Paseo de la Castellana 261, Madrid 28046, Spain. Electronic address: vsoriano@dragonet.es.
Abstract
BACKGROUND: Therapeutic options are limited for HIV-2 infected persons, largely in part due to the lack of susceptibility to HIV-1 non-nucleoside reverse transcriptase inhibitors and poor susceptibility to some HIV-1 protease inhibitors. This is particularly worrisome for HIV-2 patients with prior antiretroviral failure. OBJECTIVES: Report the virological response to dolutegravir in HIV-2-infected individuals. STUDY DESIGN: Retrospective observational assessment of all HIV-2 individuals treated with dolutegravir in Spain. RESULTS: From 297 HIV-2-infected individuals recorded at the Spanish national registry, 26% received antiretroviral therapy. Six out of 8 failing on raltegravir selected for integrase resistance mutations N155H (4), Y143G (1) and Q148R (1). Two patients bearing N155H subsequently received dolutegravir. Both experienced initially more than 1.5 log drop in plasma HIV-2 RNA and significant CD4 gains. Whereas one kept on undetectable viremia 6 months later, the other experienced viral rebound. CONCLUSION: Dolutegravir may be a good therapeutic option for patients with HIV-2 infection, including those that previously failed other integrase inhibitors.
BACKGROUND: Therapeutic options are limited for HIV-2 infectedpersons, largely in part due to the lack of susceptibility to HIV-1 non-nucleoside reverse transcriptase inhibitors and poor susceptibility to some HIV-1 protease inhibitors. This is particularly worrisome for HIV-2patients with prior antiretroviral failure. OBJECTIVES: Report the virological response to dolutegravir in HIV-2-infected individuals. STUDY DESIGN: Retrospective observational assessment of all HIV-2 individuals treated with dolutegravir in Spain. RESULTS: From 297 HIV-2-infected individuals recorded at the Spanish national registry, 26% received antiretroviral therapy. Six out of 8 failing on raltegravir selected for integrase resistance mutations N155H (4), Y143G (1) and Q148R (1). Two patients bearing N155H subsequently received dolutegravir. Both experienced initially more than 1.5 log drop in plasma HIV-2 RNA and significant CD4 gains. Whereas one kept on undetectable viremia 6 months later, the other experienced viral rebound. CONCLUSION:Dolutegravir may be a good therapeutic option for patients with HIV-2 infection, including those that previously failed other integrase inhibitors.
Authors: Robert A Smith; Dana N Raugi; Vincent H Wu; Christopher G Zavala; Jennifer Song; Khardiata Mbaye Diallo; Moussa Seydi; Geoffrey S Gottlieb Journal: Antimicrob Agents Chemother Date: 2019-04-25 Impact factor: 5.191
Authors: Selly Ba; Dana N Raugi; Robert A Smith; Fatima Sall; Khadim Faye; Stephen E Hawes; Papa Salif Sow; Moussa Seydi; Geoffrey S Gottlieb Journal: Clin Infect Dis Date: 2018-10-30 Impact factor: 9.079
Authors: Robert A Smith; Vincent H Wu; Jennifer Song; Dana N Raugi; Khardiata Diallo Mbaye; Moussa Seydi; Geoffrey S Gottlieb Journal: J Infect Dis Date: 2022-08-26 Impact factor: 7.759
Authors: Robert A Smith; Vincent H Wu; Christopher G Zavala; Dana N Raugi; Selly Ba; Moussa Seydi; Geoffrey S Gottlieb Journal: Antimicrob Agents Chemother Date: 2018-09-24 Impact factor: 5.191
Authors: Robert A Smith; Dana N Raugi; Charlotte Pan; Papa Salif Sow; Moussa Seydi; James I Mullins; Geoffrey S Gottlieb Journal: Retrovirology Date: 2015-02-05 Impact factor: 4.602
Authors: Hannah J Barbian; Raven Jackson-Jewett; Corrine S Brown; Frederic Bibollet-Ruche; Gerald H Learn; Timothy Decker; Edward F Kreider; Yingying Li; Thomas N Denny; Paul M Sharp; George M Shaw; Jeffrey Lifson; Edward P Acosta; Michael S Saag; Katharine J Bar; Beatrice H Hahn Journal: Retrovirology Date: 2017-06-02 Impact factor: 4.602
Authors: S Jespersen; F Månsson; J Lindman; C Wejse; C Medina; Z J da Silva; DdS Te; P Medstrand; J Esbjörnsson; B L Hønge Journal: AIDS Res Ther Date: 2020-02-04 Impact factor: 2.250